Nuvectra Corporation (NASDAQ:NVTR) Files An 8-K Entry into a Material Definitive AgreementItem 9.01
Entry into a Material Definitive Agreement.
On August 21, 2017, Greatbatch Ltd. (“Greatbatch”) executed and delivered to Nuvectra Corporation (“Nuvectra”) an Amendment No. 1 to the Supply Agreement, with an effective date of July 21, 2017 (the “Amendment”). The Amendment amends the Supply Agreement between Nuvectra (formerly QiG Group, LLC) and Greatbatch dated March 14, 2016 (the “Supply Agreement”). Under the terms of the Amendment, Greatbatch and Nuvectra agreed to modify the pricing of certain products and the amount of minimum product purchases required to be purchased by Nuvectra on an annual basis from Greatbatch.
The foregoing description is not complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 10.1 to this Current Report and incorporated by reference into this Item 9.01.
|
Item 9.01 |
Financial Statements and Exhibits. |
(d)Exhibits.
| Exhibit No. | Description |
|
10.1 |
Amendment No. 1 to the Supply Agreement, fully executed on August 21, 2017 and effective as of July 21, 2017, between Nuvectra Corporation and Greatbatch Ltd.± |
± Confidential treatment has been requested for certain portions of this Exhibit to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, which portions have been omitted and filed separately with the Securities and Exchange Commission.
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
August 23, 2017 |
NUVECTRA CORPORATION |
|
By:/s/ Walter Z. Berger |
|
|
Walter Z. Berger, |
|
|
Chief Operating Officer and Chief Financial Officer |
|
EXHIBIT INDEX
| Exhibit No. | Description |
|
10.1 |
Amendment No. 1 to the Supply Agreement, fully executed on August 21, 2017 and effective as of July 21, 2017, between Nuvectra Corporation and Greatbatch Ltd.± |
± Confidential treatment has been requested for certain portions of this Exhibit Nuvectra Corp ExhibitEX-10.1 2 ex10-1.htm EXHIBIT 10.1 ex10-1.htm Exhibit 10.1 AMENDMENT NO. 1 TO THE SUPPLY AGREEMENT THIS AMENDMENT NO. 1 TO THE SUPPLY AGREEMENT (this “Amendment”),…To view the full exhibit click here
About Nuvectra Corporation (NASDAQ:NVTR)
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company’s neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).